Skip to main content

Advertisement

SpringerLink
Log in

The Impact of Oral Intake of Dydrogesterone on Fetal Heart Development During Early Pregnancy

  • Original Article
  • Published:
Pediatric Cardiology Aims and scope Submit manuscript

Abstract

Congenital heart disease is the most frequent form of congenital anomaly in newborn infants and accounts for more than a quarter of all serious congenital afflictions worldwide. A genetic etiology is identified in <20 % of cases of congenital heart defects, and in most cases the etiology remains a mystery. In the context of the health burden caused by congenital heart disease, the contribution of non-inherited risk factors is important especially if it turns out to be caused by a drug which can be avoided during pregnancy. We sought to determine whether maternal dydrogesterone treatment in early pregnancy is associated with congenital heart disease in the infant. We conducted a retrospective case–control study of birth defects and associated risk factors. Data were obtained and compared between 202 children born with congenital heart disease and a control group consisting of 200 children. All children were born in the period of 2010–2013. Dydrogesterone exposure was defined as any reported use during the first trimester of pregnancy. Exclusion criteria included stillbirths, children with chromosomal abnormalities and infants of mothers with chronic medical illnesses, e.g., diabetes. Binary logistic regression analyses were used to analyze the data and attempt to identify a causal relationship between drug exposure and congenital heart disease. Mothers of children born with congenital heart disease received more dydrogesterone during first trimester of pregnancy than mothers of children in the control group [adjusted odds ratio 2.71; (95 % CI 1.54–4.24); P = 0.001]. We identified a positive association between dydrogesterone usage during early pregnancy and congenital heart disease in the offspring. Nevertheless, further studies are needed to confirm these results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bracken MD, Holford TR, White C et al (1978) Role of oral contraception in congenital malformations of offspring. Int J Epidemiol 7:309

    Article  CAS  PubMed  Google Scholar 

  2. Chard T (1991) Frequency of implantation and early pregnancy loss in natural cycles. Baillieres Clin Obstet Gynaecol 5:179–189

    Article  CAS  PubMed  Google Scholar 

  3. Greenberg G, Inman WHW, Weatherall JAC et al (1977) Maternal drug histories and congenital abnormalities. BMJ 2:853

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. Harlap S, Prywes R, Davies AM (1975) Birth defects and estrogens and progesterones in pregnancy. Lancet 1:682

    Article  CAS  PubMed  Google Scholar 

  5. Harlap S, Shiono PH, Ramcharan S (1985) Congenital abnormalities in the offspring of women who used oral and other contraceptives around the time of conception. Int J Fertil 30:39

    CAS  PubMed  Google Scholar 

  6. Heinonen OP, Slone D, Monson RR et al (1976) Cardiovascular birth defects in antenatal exposure to female sex hormones. N Engl J Med 296:67

    Article  Google Scholar 

  7. Heinonen OP, Slone D, Shapiro S (1979) Birth defects and drugs in pregnancy. Littleton Teratol 20(3):487–488

    Google Scholar 

  8. Hook EB (1994) Cardiovascular birth defects and prenatal exposure to female sex hormones: a reevaluation of data from a large prospective study. Teratology 49:162

    Article  CAS  PubMed  Google Scholar 

  9. Janerich DT, Dugan JM, Standfast SJ et al (1977) Congenital heart disease and prenatal exposure to exogenous sex hormones. BMJ 1:1058

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Jenkins KJ, Correa A, Feinstein JA, Botto L, Britt AE, Daniels SR, Elixson M, Warnes CA, Webb CL (2007) Noninherited risk factors and congenital cardiovascular defects: current knowledge: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young: endorsed by the American Academy of Pediatrics. Circulation 115(23):2995–3014

    Article  PubMed  Google Scholar 

  11. Kline J (1989) Conception to birth—epidemiology of prenatal development. Monographs in epidemiology and biostatistics, vol 14. Oxford University Press, Oxford

  12. Kullander S, Kallen B (1976) A prospective study of drugs and pregnancy. Acta Obstet Gynecol Scand 55:221

    Article  CAS  PubMed  Google Scholar 

  13. Levy EP, Cohen A, Fraser FC (1973) Hormone treatment during pregnancy and congenital heart disease. Lancet 1:611

    Article  CAS  PubMed  Google Scholar 

  14. Lewallen S (1998) Epidemiology in practice: case–control studies. Community Eye Health 11(28):57–58

    PubMed Central  CAS  PubMed  Google Scholar 

  15. Michaelis J, Michaelis H, Gluck E et al (1983) Prospective study of suspected associations between certain drugs administered during early pregnancy and congenital malformations. Teratology 27:57

    Article  CAS  PubMed  Google Scholar 

  16. Mitchell SC, Korones SB, Berendes HW (1971) Congenital heart disease in 56,109 births. Incidence and natural history. Circulation 43:323–332

    Article  CAS  PubMed  Google Scholar 

  17. Nora JJ, Nora AH, Blum J et al (1978) Exogenous progestogen and estrogen implicated in birth defects. JAMA 240:837

    Article  CAS  PubMed  Google Scholar 

  18. Richards AA, Santos LJ, Nichols HA, Crider BP, Elder FF, Hauser NS, Zinn AR, Garg V (2008) Cryptic chromosomal abnormalities identified in children with congenital heart disease. Pediatr Res 64(4):358–363

    Article  PubMed  Google Scholar 

  19. Royal College of General Practitioners (1976) The outcome of pregnancy in former oral contraceptive users. Br J Obstet Gynaecol 83:608

    Article  Google Scholar 

  20. Savolainen E, Saksela E, Saxen L (1981) Teratogenic hazards of oral contraceptives analyzed in a national malformation register. Am J Obstet Gynecol 140:521

    CAS  PubMed  Google Scholar 

  21. Stirrat GM (1990) Recurrent miscarriage. Lancet 336:673–675

    Article  CAS  PubMed  Google Scholar 

  22. Torfs C, Milkovich L, Van Den Berg BJ (1981) The relationship between hormonal pregnancy tests and congenital abnormalities: a prospective study. Am J Epidemiol 113:563

    CAS  PubMed  Google Scholar 

  23. Varma TR, Morsman J (1982) Evaluation of the early use of proluton-depot (hydroxyprogesterone hexanoate) in early pregnancy. Int J Gynaecol Obstet 20:13

    Article  CAS  PubMed  Google Scholar 

  24. Vessey MP (1979) Outcome of pregnancy in women using different methods of contraception. Br J Obstet Gynaecol 86:548

    Article  CAS  PubMed  Google Scholar 

  25. Wilcox AJ, Weinberg CR, O’Connor JF et al (1988) Incidence of early loss of pregnancy. N Engl J Med 319:189–194

    Article  CAS  PubMed  Google Scholar 

  26. Wiseman RA, Dodds-Smith IC (1984) Cardiovascular birth defects and antenatal exposure to female sex hormones: a reevaluation of some base data. Teratology 30:359

    Article  CAS  PubMed  Google Scholar 

  27. Zaqout M, Aslem ES, Oweida FS, De Wolf D (2014) Prevalence of congenital heart disease among Palestinian children born in the Gaza Strip. Cardiol Young 24(5):905–909

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We thank the medical director of Al Nassr Pediatric Hospital Dr Mostafa Al Kahlout and the pediatricians for their cooperation.

Conflict of interest

The authors declare they have no conflict of interest to disclose.

Author information

Authors and Affiliations

  1. Department of Pediatric Cardiology, Ghent University Hospital, De Pintelaan 185, 9000, Ghent, Belgium

    Mahmoud Zaqout, Joseph Panzer & Daniel De Wolf

  2. Department of Pediatric Cardiology, Abd Al Aziz Al Rantisi Specialist Pediatric Hospital, Gaza, Palestine

    Emad Aslem

  3. Department of Public Health, Al Quds University, Gaza, Palestine

    Mazen Abuqamar

  4. Imperial Health Care Trust, London, England

    Osama Abughazza

Authors
  1. Mahmoud Zaqout
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emad Aslem
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mazen Abuqamar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Osama Abughazza
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Joseph Panzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Daniel De Wolf
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mahmoud Zaqout.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zaqout, M., Aslem, E., Abuqamar, M. et al. The Impact of Oral Intake of Dydrogesterone on Fetal Heart Development During Early Pregnancy. Pediatr Cardiol 36, 1483–1488 (2015). https://doi.org/10.1007/s00246-015-1190-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00246-015-1190-9

Keywords

Search

Navigation